CLVT · Clarivate Plc

On July 3, 2026, Clarivate Plc announced a definitive agreement to sell its Life Sciences and Healthcare business to an affiliate of Altaris, LLC for a total consideration of $600 million. The deal consists of $500 million in cash at closing, $25 million in deferred consideration tied to transition services, and a $75 million senior unsecured note issued by the buyer. The divestiture streamlines Clarivate’s focus on its remaining portfolio and provides significant upfront liquidity. The transaction is structured as a stock and asset purchase and does not require shareholder approval, but is subject to customary regulatory clearances, including HSR Act approval. Closing is anticipated by the end of calendar year 2026. Concurrently, Clarivate entered into a retention agreement with Henry Levy, President of the business, to ensure leadership continuity through closing. The agreement provides for accelerated vesting of his unvested RSUs upon closing and enhanced severance protections if he is terminated without cause within six months post-closing. The buyer has secured equity and debt financing commitments, with a $33 million termination fee payable in certain scenarios, reflecting the strength of the deal. The transaction represents a strategic pivot for Clarivate, allowing it to reduce leverage and focus on core intellectual property and scientific research analytics. Investors should monitor regulatory timelines and any updates on transition services.